Achilles Therapeutics PLC ADR (ACHL)

NASDAQ
11.54
-0.16(-1.37%)
  • Volume:
    6,479
  • Bid/Ask:
    11.50/13.22
  • Day's Range:
    11.53 - 11.93

ACHL Overview

Prev. Close
11.7
Day's Range
11.53-11.93
Revenue
-
Open
11.93
52 wk Range
11.42-18.95
EPS
-
Volume
6,479
Market Cap
468.78M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
96,597
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
40,621,751
Next Earnings Date
Sep 01, 2021
What is your sentiment on Achilles Therapeutics PLC ADR?
or
Market is currently closed. Voting is open during market hours.

Achilles Therapeutics PLC ADR News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellNeutral
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellBuy

Achilles Therapeutics PLC ADR Company Profile

Achilles Therapeutics PLC ADR Company Profile

Sector
Services
Employees
153

Achilles Therapeutics plc is a clinical stage immuno-oncology biopharmaceutical company that is engaged in developing precision T cell therapies to treat multiple types of solid tumors. The Company has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The Company's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.